Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.
Buyside Digest is not affiliated with, and does not endorse, Laughing Water Capital. This analysis is provided for institutional research purposes only and is not investment advice.
Fund Returns
QTD+39.8%
YTD+33.6%
Annualized+22%
Positioning StanceNEUTRAL
Market CapSmallCap
GeographyUS
Digest Analysis
Quick Take
"The concentrated portfolio now holds significant cash following exits, with new position AnaptysBio offering 50-80% upside as GSK litigation approaches trial in July."
Executive Summary
Laughing Water Capital returned 39.8% net in Q2 2026, bringing year-to-date returns to 33.6% and 10-year annualized returns to 20.0%. The exceptional quarter was driven by three portfolio company acquisitions (Theravance, Avanos, SECURE Waste) and the doubling of the largest position. The manager emphasizes that timing was largely coincidental, but the process of identifying mispriced opportunities in forgotten corners of the market remains sound. The portfolio is currently more concentrated than typical, with a double-digit cash position providing flexibility for future deployment. New position AnaptysBio represents a special situation with 50-80% upside potential over the next 4-6 weeks, as the company faces litigation with GSK over Jemperli royalties that could result in settlement or outright acquisition. Other key positions include Liquidia awaiting a favorable patent ruling, Nextnav awaiting FCC spectrum approval, and Lifecore evaluating strategic alternatives. The manager continues to focus on idiosyncratic healthcare and special situation investments largely removed from the real economy, with distinct catalysts on the horizon to surface value while ignoring macro headlines.
Unlock Full Institutional Analysis
Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.
Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.
Signal Matrix
Market Conviction
78%
CautiousHigh
High Conviction (78%)
Portfolio is concentrated with detailed, specific position-level discussion. Manager names 8 positions with substantive commentary, provides explicit sizing (double-digit cash position, top 5 positions, largest position), and offers falsifiable catalysts with specific timeframes (July 14-17 trial, judge ruling any day now, FCC approval expected). The 15-page appendix on AnaptysBio demonstrates deep research with detailed DCF models, legal analysis, and specific price targets. Manager states nearly the entirety of his and his family's wealth is invested alongside partners. Language is declarative with clear base cases, though some hedging exists. This is high conviction with named, sized positions and clear catalysts, though not extreme concentration (5-10 core positions suggested).
Growth Outlook
15%
BearishBullish
Bearish (15%)
Manager explicitly states he has no deep thoughts on what will come next for equity markets and lists several worries including oil prices, AI consequences, global political uncertainty, and rising socialism. However, the tone is not alarmed—these are acknowledged risks rather than predictions of imminent crisis. The manager suggests healthy skepticism toward market forecasters. This is mildly cautious acknowledgment of risks without strong directional conviction, scoring slightly positive only because the manager remains invested and focused on individual opportunities rather than defensive positioning.
Risk Appetite
45%
DefensiveAggressive
Balanced (45%)
Portfolio is concentrated and fully invested in idiosyncratic special situations with near-term catalysts. Manager holds double-digit cash position but frames this as temporary following three acquisitions, not defensive positioning. He is actively hunting for new opportunities and states he will not hesitate to act when finding mispriced businesses. The cash is residual from exits, not intentional de-risking. Portfolio tilts toward risk-on through concentration in catalyst-driven situations, though not maximum exposure due to elevated cash levels.
Capital Deployment
38%
De-riskingDeploying
Net Neutral (38%)
Cash position increased to double-digits following three portfolio company acquisitions during the quarter. While manager is actively hunting for opportunities and will not hesitate to act, the current elevated cash level represents net de-risking from the start of the quarter. The manager frames this as temporary and expects to return to more typical concentration levels, but the net change from quarter start to quarter end is higher cash. This scores moderately negative for de-risking, though not aggressively so given the cash is residual from exits rather than intentional defensive positioning.
Forward Guidance
35%
CautiousExpansionary
Cautious (35%)
Manager is actively hunting for idiosyncratic opportunities and will not hesitate to act when finding good businesses dealing with problems that lead to mispricing. However, he is selective and patient, waiting for the right opportunities rather than forcing deployment. The double-digit cash position suggests he is not rushing to deploy capital. Language indicates selective adding bias with clear criteria, but not aggressive deployment. This is moderately positive action bias tempered by selectivity and patience.
Language Signal
50%
BearishBullish
Balanced (50%)
Language is balanced between opportunity and risk. Bullish language includes: exceptional quarter, fantastic launch, impressive rate, well positioned, acceptable investment returns, significant upside, lotto ticket upside. Risk language includes: things to worry about, scary headlines, bumps along the way, disappointed by price, legal overhang, volatility. The letter is more opportunity-focused than risk-focused, particularly in the detailed AnaptysBio appendix which is overwhelmingly bullish on that specific situation. Net balance tilts moderately bullish while acknowledging risks.
Perceived Risk
35%
Low RiskElevated
Moderate Risk (35%)
Manager acknowledges there are certainly things to worry about and lists specific risks: oil prices, unintended consequences from AI, global political uncertainty, and rising socialism in the U.S. However, these risks are mentioned briefly in a single paragraph near the end of the letter without detailed elaboration or alarm. The manager immediately pivots to focusing on individual businesses rather than macro risks. Risk discussion is present but not central to the letter, and the manager explicitly states he is not one of those who claims to know how these things will affect markets. This is moderate risk acknowledgment with standard caveats, not systemic warnings.
Opportunity Density
65%
ScarceAbundant
Abundant (65%)
Manager continues to find attractive opportunities in forgotten corners of the investment universe, recently adding three new healthcare positions in Q1 and AnaptysBio in Q2. He states he is actively hunting for idiosyncratic opportunities and will not hesitate to act when finding mispriced businesses. The letter describes multiple positions with attractive risk/reward profiles and near-term catalysts. However, the elevated cash position and selective language (good business, led by good people, dealing with some sort of problem) suggests opportunities require specific criteria rather than being abundant everywhere. This is selective opportunities in defined areas with active pipeline, not a broad opportunity set across all sectors.
Time Horizon
52%
Short-TermLong-Term
Multi-Year (52%)
Portfolio is characterized by shorter timelines with near-term catalysts. AnaptysBio expected to resolve in 4-6 weeks with July 14-17 trial. Liquidia ruling expected any day now. Lifecore strategic alternatives process underway. Manager describes new investments as characterized by shorter timelines, value underpinned by near-term cash flows, and limited event path risk. However, manager also emphasizes patience as the best way to take advantage of market inefficiency and states his family's wealth remains invested long-term. The fund has a 10-year track record suggesting multi-year holding periods. This is medium-term with 1-3 year thesis horizons and near-term catalyst dependency, not permanent capital or decade-plus horizon.